Browse FOSL1

Summary
SymbolFOSL1
NameFOS-like antigen 1
Aliases fra-1; FRA1; FOS-like antigen-1; Fos-related antigen 1
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus.
Domain PF00170 bZIP transcription factor
Function

-

> Gene Ontology
 
Biological Process GO:0000302 response to reactive oxygen species
GO:0001701 in utero embryonic development
GO:0001890 placenta development
GO:0006352 DNA-templated transcription, initiation
GO:0006968 cellular defense response
GO:0006979 response to oxidative stress
GO:0007028 cytoplasm organization
GO:0007292 female gamete generation
GO:0007296 vitellogenesis
GO:0007565 female pregnancy
GO:0007611 learning or memory
GO:0007612 learning
GO:0009612 response to mechanical stimulus
GO:0009615 response to virus
GO:0009629 response to gravity
GO:0009991 response to extracellular stimulus
GO:0010035 response to inorganic substance
GO:0014074 response to purine-containing compound
GO:0022412 cellular process involved in reproduction in multicellular organism
GO:0031334 positive regulation of protein complex assembly
GO:0031668 cellular response to extracellular stimulus
GO:0031960 response to corticosteroid
GO:0032570 response to progesterone
GO:0042493 response to drug
GO:0042542 response to hydrogen peroxide
GO:0043254 regulation of protein complex assembly
GO:0044089 positive regulation of cellular component biogenesis
GO:0044706 multi-multicellular organism process
GO:0044708 single-organism behavior
GO:0045787 positive regulation of cell cycle
GO:0046683 response to organophosphorus
GO:0048545 response to steroid hormone
GO:0048608 reproductive structure development
GO:0050890 cognition
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity
GO:0051384 response to glucocorticoid
GO:0051385 response to mineralocorticoid
GO:0051412 response to corticosterone
GO:0051591 response to cAMP
GO:0060674 placenta blood vessel development
GO:0061458 reproductive system development
GO:0061614 pri-miRNA transcription from RNA polymerase II promoter
GO:0071496 cellular response to external stimulus
GO:1901654 response to ketone
GO:2000142 regulation of DNA-templated transcription, initiation
GO:2000144 positive regulation of DNA-templated transcription, initiation
Molecular Function GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding
GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0000987 core promoter proximal region sequence-specific DNA binding
GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001159 core promoter proximal region DNA binding
GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
Cellular Component GO:0042734 presynaptic membrane
GO:0097060 synaptic membrane
GO:0098793 presynapse
> KEGG and Reactome Pathway
 
KEGG hsa04310 Wnt signaling pathway
hsa04380 Osteoclast differentiation
Reactome -
Summary
SymbolFOSL1
NameFOS-like antigen 1
Aliases fra-1; FRA1; FOS-like antigen-1; Fos-related antigen 1
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FOSL1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between FOSL1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
20386569Breast CarcinomaInhibit immunityFra-1 protooncogene regulates IL-6 expression in macrophages and promotes the generation of M2d macrophages. The 4T1 cells stimulate de novo overexpression of Fra-1 in RAW264.7 cells, and then Fra-1 binds to the interleukin 6 (IL-6) promoter to increase the production of the cytokine IL-6 in RAW264.7 cells.
Summary
SymbolFOSL1
NameFOS-like antigen 1
Aliases fra-1; FRA1; FOS-like antigen-1; Fos-related antigen 1
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FOSL1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFOSL1
NameFOS-like antigen 1
Aliases fra-1; FRA1; FOS-like antigen-1; Fos-related antigen 1
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FOSL1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.7050.317
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.6130.745
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.7440.512
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.730.23
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.8940.584
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.5180.806
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.3130.662
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.6680.562
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2010.862
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.7650.403
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.0750.372
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.4980.0147
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FOSL1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolFOSL1
NameFOS-like antigen 1
Aliases fra-1; FRA1; FOS-like antigen-1; Fos-related antigen 1
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FOSL1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFOSL1
NameFOS-like antigen 1
Aliases fra-1; FRA1; FOS-like antigen-1; Fos-related antigen 1
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FOSL1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FOSL1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFOSL1
NameFOS-like antigen 1
Aliases fra-1; FRA1; FOS-like antigen-1; Fos-related antigen 1
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FOSL1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFOSL1
NameFOS-like antigen 1
Aliases fra-1; FRA1; FOS-like antigen-1; Fos-related antigen 1
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FOSL1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFOSL1
NameFOS-like antigen 1
Aliases fra-1; FRA1; FOS-like antigen-1; Fos-related antigen 1
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FOSL1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFOSL1
NameFOS-like antigen 1
Aliases fra-1; FRA1; FOS-like antigen-1; Fos-related antigen 1
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FOSL1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.